Figure 2.
Master Protocol for Lung-MAP Study of Squamous Cell Lung Cancer
CLIA, Clinical Laboratory Improvement Amendments; CT, chemotherapy (docetaxel or gemcitabine); E, erlotinib; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; TT, targeted therapy.
Reproduced with permission from DR Gandara, MD.